Filing Flows

Filing Flows › Companies › Crispr Therapeutics AG › Cash flow

Crispr Therapeutics AG cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$90.1M in Q3 2026 · −$377M over twelve months

Operating cash flow−$89.7M
Capital spending−$414K
Free cash flow−$90.1M

Analysis

In Q3 2026, Crispr Therapeutics AG generated −$89.7M of operating cash flow and spent $414K on capital projects, leaving free cash flow of −$90.1M. That is $5.4M less than in Q3 2025 (−$84.7M).

Over the twelve months to Sep 30, 2026, operating cash flow was −$375M; the largest uses were other investing ($441M), operating cash flow ($375M), capital spending ($2.1M); besides operations, cash came from other financing ($585M), shares issued ($135M); the cash balance fell by $98.0M.

Operating cash flow was −$89.7M against net income of −$111M. The largest differences: payables +$20.6M, stock-based pay +$18.0M, deferred revenue −$12.6M.

Free cash flow

Crispr Therapeutics AG: free cash flow by quarterCrispr Therapeutics AG: free cash flow by quarter−$50.3MQ4 2024−$54.2MQ1 2025−$114MQ2 2025−$84.7MQ3 2025−$93.1MQ4 2025−$109MQ1 2026−$84.1MQ2 2026−$90.1MQ3 2026
Operating cash flow less capital spending.
Crispr Therapeutics AG: operating cash flow against capital spendingCrispr Therapeutics AG: operating cash flow against capital spendingOperating cash flowCapital spending−$50.0M$254KQ4 2024−$53.9M$206KQ1 2025−$114M$117KQ2 2025−$84.6M$74KQ3 2025−$92.6M$517KQ4 2025−$109M$504KQ1 2026−$83.5M$648KQ2 2026−$89.7M$414KQ3 2026
Latest (Q3 2026): Operating cash flow −$89.7M, Capital spending $414K.

Capital allocation, year by year

Crispr Therapeutics AG: where the cash came from (up) and went (down), by fiscal yearCrispr Therapeutics AG: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedCapital spendingFY2021: Operating cash flow $539MFY2021: Shares issued $251MFY2021: Capital spending −$81.7M$790MFY2021FY2022: Operating cash flow −$496MFY2022: Shares issued $38.6MFY2022: Capital spending −$37.2M$38.6MFY2022FY2023: Operating cash flow −$260MFY2023: Shares issued $62.7MFY2023: Capital spending −$9.5M$62.7MFY2023FY2024: Operating cash flow −$143MFY2024: Shares issued $332MFY2024: Capital spending −$1.9M$332MFY2024FY2025: Operating cash flow −$345MFY2025: Shares issued $426MFY2025: Capital spending −$914K$426MFY2025
Over these 5 years operating cash flow totalled −$705M; the largest uses were operating cash flow ($1.2B) and capital spending ($131M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$2.3B
Debt$587M
Net cash$1.7B
Cash runway6.0 years

Crispr Therapeutics AG is burning cash: its operations consume cash, a free cash flow of −$377M a year at the current rate against $2.3B of cash and investments: a runway of about 6.0 years before any new financing.

Where the cash came from and went

Crispr Therapeutics AG: sources (+) and uses (−) of cash, Q3 2026Crispr Therapeutics AG: sources (+) and uses (−) of cash, Q3 2026Cash drawn (+) / kept (−)$99.3MOperating cash flow−$89.7MOther investing−$13.7MShares issued$4.5MCapital spending−$414KExchange rates$6K
Crispr Therapeutics AG: sources (+) and uses (−) of cash, TTM to Q3 2026Crispr Therapeutics AG: sources (+) and uses (−) of cash, TTM to Q3 2026Other financing$585MOther investing−$441MOperating cash flow−$375MShares issued$135MCash drawn (+) / kept (−)$98.0MCapital spending−$2.1MExchange rates−$19K

From profit to cash

Crispr Therapeutics AG: net income to operating cash flow, Q3 2026Crispr Therapeutics AG: net income to operating cash flow, Q3 2026Net income−$111MDepreciation & amortization$4.2MStock-based pay$18.0MOther non-cash−$2.5MPayables$20.6MDeferred revenue−$12.6MPrepaid and other assets−$4.2MOther liabilities$32KOperating cash flow−$89.7M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026−$89.7M−$414K—$4.5M$99.3M−$90.1M
Q2 2026−$83.5M−$648K—$8.3M$132M−$84.1M
Q1 2026−$109M−$504K$600M$5.4M−$72.2M−$109M
Q4 2025−$92.6M−$517K—$116M−$61.1M−$93.1M
Q3 2025−$84.6M−$74K—$297M−$92.9M−$84.7M
Q2 2025−$114M−$117K—$2.3M$41.6M−$114M
Q1 2025−$53.9M−$206K—$10.6M$63.1M−$54.2M
Q4 2024−$50.0M−$254K—$16.9M−$72.6M−$50.3M

Crispr Therapeutics AG: income statement and cash flow

Crispr Therapeutics AG, Q3 2026: revenue $12.7M (14× year over year). The chart follows the revenue to costs, profit and cash.

Crispr Therapeutics AG: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.